MicroRNAs and benign biliary tract diseases.
MicroRNAs and benign biliary tract diseases.
复制标题
DOI：
10.1055/s-0034-1397346
复制
发表时间：
2015-02
影响因子：
4.2
通讯作者：
LaRusso NF
中科院分区：
文献类型：
--
作者：
Gradilone SA;O'Hara SP;Masyuk TV;Pisarello MJ;LaRusso NF
胆管细胞是排列在胆道树上的上皮细胞，只占肝细胞总数的一小部分(3-5%)，但它们负责分泌高达每日胆汁总量的40%。此外，胆管细胞是影响胆道的多种肝病的靶点，胆管病；对于这些疾病中的大多数，其病理机制尚不清楚。MicroRNAs(MiRNAs)是一种小的、非编码的RNA，在转录后调节基因的表达。因此，不足为奇的是，改变的miRNA图谱是胆管疾病病理生物学中涉及的几种蛋白质调节失调的基础，并显示出作为诊断和预后工具的希望。在此，作者综述了近年来有关miRNAs在几种胆管病(即纤维炎性胆管病和多囊肝病)发病机制中作用的研究，讨论了miRNAs作为预后和诊断工具的价值，并对进一步研究提出了建议。
Cholangiocytes, the epithelial cells lining the biliary tree, represent only a small portion of the total liver cell population (3–5%), but they are responsible for the secretion of up to 40% of total daily bile volume. In addition, cholangiocytes are the target of a diverse group of liver diseases affecting the biliary tract, the cholangiopathies; for most of these conditions, the pathological mechanisms are unclear. MicroRNAs (miRNAs) are small, noncoding RNAs that posttranscriptionally regulate gene expression. Thus, it is not surprising that altered miRNA profiles underlie the dysregulation of several proteins involved in the pathobiology of the cholangiopathies, as well as showing promise as diagnostic and prognostic tools. Here the authors review recent work relevant to the role of miRNAs in the etiopathogenesis of several of the cholangiopathies (i.e., fibroinflammatory cholangiopathies and polycystic liver diseases), discuss their value as prognostic and diagnostic tools, and provide suggestions for further research.
登录
查看更多内容
影响因子：
1.9
作者：
Boberg, KM;Bergquist, A;Schrumpf, E
通讯作者：
Schrumpf, E
影响因子：
13.5
作者：
Braconi, Chiara;Huang, Nianyuan;Patel, Tushar
通讯作者：
Patel, Tushar
miR-373 负向调节肝门部胆管癌中的甲基 CpG 结合域蛋白 2 (MBD2)
影响因子：
3.1
作者：
Chen, Yongjun;Luo, Jian;Zou, Shengquan
通讯作者：
Zou, Shengquan
microRNA表达模式在人肝内胆管癌中的作用。
影响因子：
25.7
作者：
Chen, Lei;Yan, He-Xin;Wang, Hong-Yang
通讯作者：
Wang, Hong-Yang
影响因子：
25.7
作者：
Bergquist, A;Ekbom, A;Broomé, U
通讯作者：
Broomé, U